Hawaii Biotech, Inc. (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. We have developed a proprietary protein production platform that is applicable to the production of vaccine antigens. Our lead vaccine candidates target the West Nile virus and the viruses responsible for seasonal influenza. A dengue vaccine is also under development for individuals traveling to or living in dengue endemic areas.
HBI has built a management team with relevant experience at companies such as Lederle, GlaxoSmithKline, QED Technologies, Syngenta, Chiron and Viagene. Collaborators, past and present, include scientists from Harvard Medical School; the University of Texas Medical Branch, Galveston; the University of Hawaii; the Walter Reed Army Institute of Research; the U.S. Army Medical Research Institute for Infectious Disease (USAMRIID); the Southwest Foundation for Biomedical Research; and the Centers for Disease Control and Prevention.
